Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Why Xpeng a Worthwhile Gamble for Speculators

By Chris Lau, InvestorPlace Contributor

XPEV stock is a long way from its 52-week high. While while other EV firms are more attractive, this one could pop even higher.

2020 In Review — 9 Great (And Not-So-Great) Calls

By Chris Lau, InvestorPlace Contributor

Technology and biotech stocks brought in more winning picks than usual, thanks partly to the strong stock market. Here are some of my best calls.

Don’t Let the Recent Dip Spook You When It Comes to Palantir Stock

By Chris Lau, InvestorPlace Contributor

Palantir announced software sales contracts with the government health agency and army but the dollar value did not impress the market.

JMIA Stock Is Flying High But What Is This e-Commerce Really Worth?

By Chris Lau, InvestorPlace Contributor

Jumia is a five-bagger returning stock in 2020 as investors bet on this African-based retailer becoming the next Amazon.

Why Pfizer is the Cheapest Coronavirus Vaccine Play

By Chris Lau, InvestorPlace Contributor

PFE stock does not include any value to the Pfizer-BioNTech partnership and the developments of a game-changing Covid-19 vaccine.

Load More